Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$6.09MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael E. McFadden
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 71
- Beta
- 2.24
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 7.95
Financials
Revenue
$6.09M+108.0%Net Income
$-8.79MEBITDA
$-6.34MFree Cash Flow
$-6.96MEPS (diluted)
$-0.40Shares Outstanding (diluted)
21.77M+204217.4%Operating Expenses
$13.46MCash & Debt
$41.38MReturn of Capital
$0.00Revenue by Segment (annual)
$433.2KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.22M | $-20.67M | $-1.17 |
| 2024 | $0.00 | $-14.64M | $-2.02 |
| 2023 | $0.00 | $-13.77M | $-3.84 |
| 2022 | $0.00 | $-16.28M | $-6.05 |
| 2021 | $0.00 | $-24.91M | $-11.79 |
| 2020 | $0.00 | $-7.39M | $-3.56 |
| 2019 | $0.00 | $-118.6K | $-3.60 |
| 2018 | $0.00 | $-43.2K | $-0.91 |
Valuation
ACOGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-51.72%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·53d ago·Positive
Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·53d ago·Negative
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.65 per share a year ago.
View source ↗ - Newsmarketbeat.com·53d ago·Positive
Alpha Cognition Q2 Earnings Call Highlights Alpha Cognition NASDAQ: ACOG reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer's treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter, as the company cited growing prescriber adoption and deeper use in long-term care facilities.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.33 per share
Typical surprise -2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.40 vs $-0.39miss
- Thu, May 14$-0.37 vs $-0.41beat
- Thu, Mar 26$-0.30 vs $-0.27miss
- Thu, Nov 13$-0.08 vs $-0.43beat
- Thu, Aug 14$-0.65 vs $-0.46miss
- Thu, May 15$-0.20 vs $-0.58beat
Estimates and results for ACOG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACOG officers and directors.
- Bought
- $8.2m
- Sold
- $250k
61 trades
1 trade
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Wills Robert Jamesbought
38 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACOG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.